Evaluation of the NV-VPAC1 Prostate Cancer (PCa) Urine Diagnostic Test in Subjects With Biopsy-confirmed Prostate Cancer, Benign Prostatic Hypertrophy, or Bladder/Kidney Stones.
Status
Conditions
Treatments
Details and patient eligibility
About
This is a double-blind, study to evaluate the performance of NV-VPAC1 PCa Urine Diagnostic Test in three distinct populations being treated at the Intermountain Urology Clinic. The first population (positive control) is comprised of men with biopsy-confirmed PCa who are scheduled for prostatectomy. The second population (negative control) is comprised of men with benign prostatic hypertrophy (BPH) who are scheduled for transurethral resection of the prostate (TURP). The third population (negative control) is comprised of men or women with bladder/kidney stones who are scheduled for a cystoscopy.
Enrollment
Sex
Ages
Volunteers
Inclusion and exclusion criteria
Subjects with prostate cancer
Inclusion Criteria:
- Males 18-80 years of age
- Biopsy-confirmed prostate cancer
- Scheduled within 2 weeks for prostatectomy
- Signed informed consent
Exclusion Criteria:
- Presence or history of another cancer diagnosis, with the exception of certain skin cancers
- Currently treated with finasteride (Proscar®, Propecia®), dutasteride (Avodart®) or anti-androgen therapy (Lupron®)
- Participated in a clinical study with an investigational drug within 2 weeks of the screening visit.
Subjects with benign prostatic hypertrophy
Inclusion Criteria:
- Males 18-80 years of age
- Diagnosis of BPH made by clinical symptoms (e.g., enlarged prostate, dribbling urine stream, frequent and urgent urination)
- Scheduled within 2 weeks for TURP
- Signed informed consent
Exclusion Criteria:
- Presence or history of any cancer diagnosis, with the exception of certain skin cancers
- Currently treated with finasteride (Proscar®, Propecia®) or dutasteride (Avodart®)
- Participated in a clinical study with an investigational drug within 2 weeks of the screening visit.
Subjects with bladder/kidney stones
Inclusion Criteria:
- Males or females 18-80 years of age
- Diagnosed with bladder/kidney stones
- Scheduled within 2 weeks for cystoscopy
- Signed informed consent
Exclusion Criteria:
- Presence or history of any cancer diagnosis, with the exception of certain skin cancers
- Participated in a clinical study with an investigational drug within 2 weeks of the screening visit.
Trial design
45 participants in 3 patient groups
Trial contacts and locations
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal